https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45183 Wed 26 Oct 2022 14:32:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30922 Wed 24 Nov 2021 15:50:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18342 Wed 24 Jun 2015 12:25:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40302 Wed 13 Mar 2024 08:50:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47988 Wed 13 Mar 2024 07:50:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13395 Wed 11 Apr 2018 17:06:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7540 Wed 11 Apr 2018 16:40:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7599 Wed 11 Apr 2018 16:00:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23650 Wed 11 Apr 2018 15:01:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5071 Wed 11 Apr 2018 13:20:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16778 Wed 11 Apr 2018 12:49:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5069 Wed 11 Apr 2018 10:11:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49013 Wed 03 May 2023 12:24:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48999 Wed 03 May 2023 12:03:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37741 0.2, with one study reporting a higher value of 0.8. Main conclusions: Successful post-amputation healing outcomes were reported at mean toe systolic blood pressure ⩾30 mmHg, and the results varied considerably between the studies. Further research should identify whether variables, including amputation level, method of wound closure and length of post-operative follow-up periods, affect the values of toe systolic blood pressure and toe-brachial pressure index observed in this review.]]> Wed 03 Aug 2022 10:31:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35278  0 MD: –5.10; 95% CI: –8.74 to −1.46; d₃–₄efs > 0; MD: –4.40; 95% CI: –7.55 to −1.25). Conclusion: Fluoride varnish applied biannually over 2 years is effective at reducing ECC in Indigenous children. Motivational interviewing has some benefit in caries prevention. Further research is required to test other preventive programmes.]]> Tue 09 Jul 2019 10:15:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34981 Tue 03 Sep 2019 18:19:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34972 1 paediatric rheumatology case in the past month. Furthermore, 67.2% of participants felt their undergraduate education in paediatric rheumatology was inadequate. “Journals” or “texts books” were used by 49.3% of participants as their primary source of continuing professional development (CPD) and 39.3% of participants indicated that they did not undertake any CPD related to paediatric rheumatology. Small group and online education were perceived to be potentially of “great benefit” for CPD. Conclusion: This paper highlights allied health professionals’ and nurses’ perceived inadequacy of their undergraduate education in paediatric RD and their low confidence in recognising and treating RD. Undergraduate and postgraduate education opportunities focusing on interprofessional collaboration should be developed to address this workforce deficiency.]]> Tue 03 Sep 2019 17:57:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45369 Thu 27 Oct 2022 15:02:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48866 Thu 13 Apr 2023 10:01:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52227 Thu 05 Oct 2023 10:29:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31245 Sat 24 Mar 2018 08:44:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12957 Sat 24 Mar 2018 08:18:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28319 Ganoderma lucidum (also known as lingzhi or reishi) is a mushroom that has been consumed for its broad medicinal properties in Asia for over 2000 years. G lucidum is becoming increasingly popular in western countries as a complementary medicine for cardiovascular health. Objectives: To evaluate the effectiveness of G lucidum for the treatment of pharmacologically modifiable risk factors of cardiovascular disease in adults.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 6 of 12, 2014) on The Cochrane Library, MEDLINE (OVID, 1946 to June week 3 2014), EMBASE (OVID, 1980 to 2014 week 26), Science Direct (1823 to 2013), Current Controlled Trials (1990 to 2013), Australian New Zealand Clinical Trials Registry (2005 to 2013), Chinese Biomedical Literature Database (2007 to 2013), Chinese Medical Current Contents (2007 to 2013) and other databases. We checked reference lists of included studies, contacted content experts and handsearched The International Journal of Medicinal Mushrooms. We applied no language or publication restrictions. Selection criteria: Randomised controlled trials and controlled clinical trials of G lucidum for the treatment of cardiovascular risk factors. Primary outcomes were blood glucose level, blood pressure and lipid profile. Data collection and analysis: Two authors independently selected trials, assessed risk of bias and cross checked data extraction and analysis. A third author arbitrated in the event of disagreement. Main results: Five trials with a total of 398 participants were eligible for inclusion. Of these, one study was published in Chinese and translated to English; one study was published but study authors provided the additional data used in this review; one study was unpublished and the study authors provided data; and two studies did not provide comparison group data suitable for statistical analyses. The three studies from which data were used for statistical analyses compared G lucidum (1.4 g to 3 g per day) to placebo over 12 to 16 weeks of intervention. Although inclusion criteria varied, all participants of these three studies had type 2 diabetes mellitus. Of the five included studies, risk of bias was low for one study and unclear for the remaining four. Results from two studies showed that G lucidum was not associated with statistically or clinically significant reduction in HbA1c (WMD -0.10%; 95% CI -1.05% to 0.85%; 130 participants), total cholesterol (WMD -0.07mmol/L; 95% CI -0.57 mmol/L to 0.42 mmol/L; 107 participants ), low-density lipoprotein cholesterol (WMD 0.02 mmol/L; 95% CI -0.41 mmol/L to 0.45 mmol/L; 107 participants), or body-mass index (WMD -0.32 kg/m²; 95% CI -2.67 kg/m² to 2.03 kg/m²; 107 participants). All other analyses were from a single study of 84 participants. We found no improvement for fasting plasma glucose (WMD 0.30 mmol/L; 95% CI -0.95 mmol/L to 1.55 mmol/L). Measures of post-prandial blood glucose level found inconsistent results, being in favour of placebo for '2-hour post-prandial blood glucose' (WMD 0.7 mmol/L; 95% CI 0.29 mmol/L to 1.11 mmol/L) and in favour of G lucidum for 'plasma glucose under the curve at 4th hour' (WMD -49.4mg/dL/h; 95% CI -77.21 mg/dL/h to -21.59 mg/dL/h). As the Minimal Clinical Important Differences are unknown, the clinical significance of this effect is unclear. There were no statistically significant differences between groups for blood pressure or triglycerides. Participants who took G lucidum for four months were 1.67 times (RR 1.67 95% CI 0.86 to 3.24) more likely to experience an adverse event than those who took placebo but these were not serious side effects. Authors' conclusions: Evidence from a small number of randomised controlled trials does not support the use of G lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus. Future research into the efficacy of G lucidum should be placebo-controlled and adhere to clinical trial reporting standards.]]> Sat 24 Mar 2018 07:25:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48230 Mon 08 May 2023 10:28:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52793 Fri 27 Oct 2023 14:08:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33971 Fri 25 Jan 2019 14:41:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39967 n = 39 of 111 participants or 35.1%) was associated with lower levels of self-perceived foot function (r = − 0.20, n = 107, p = 0.04). Conclusion: We found that community-based foot health care services that are culturally safe are utilised by Aboriginal and Torres Strait Islander Peoples not currently at high risk of foot complications. This supports the use of culturally safe foot care services to improve engagement with preventative foot care. Future research should continue to be driven by Aboriginal and Torres Strait Islander Peoples and investigate ways to implement additional screening measures and undertake prospective evaluation of the impact of such services on health related outcomes in these communities.]]> Fri 15 Jul 2022 10:18:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52997 Fri 03 Nov 2023 16:07:56 AEDT ]]>